TY - JOUR
T1 - An update on antidepressant use and suicidality in pediatric depression
AU - Adegbite-Adeniyi, Clara
AU - Gron, Brittany
AU - Rowles, Brieana M.
AU - Demeter, Christine A.
AU - Findling, Robert L.
PY - 2012/10
Y1 - 2012/10
N2 - Introduction: In 2003, public health advisories in North America and Europe regarding suicidality associated with selective serotonin reuptake inhibitors (SSRIs) led to the addition of black box warnings to antidepressant package inserts in 2004. Subsequently, a series of events appeared to result from these regulatory actions. Areas covered: This review provides an overview of the temporal associations of regulatory agencies' actions in North America and Europe with rates of depression diagnoses, pediatric antidepressant prescription rates, follow-up visits to physicians prescribing antidepressants, and rates of completed suicide and suicidal ideation in children and adolescents. In addition, evidence-based predictors of suicidal behavior and suicide risk, as provided by large, multisite studies of depressed children and adolescents, are outlined. Finally, this review considers key advancements in the study of young patients at risk for suicide and describes innovations in current research methodology, to more accurately identify suicidality and the relationship to antidepressant use within this vulnerable patient population. Expert opinion: Evaluating the role of antidepressants in those youths who do not respond to evidence-based psychotherapeutic interventions may be a useful future research direction. Until more data are available, however, closely monitored antidepressant treatment in combination with CBT may provide the most benefit.
AB - Introduction: In 2003, public health advisories in North America and Europe regarding suicidality associated with selective serotonin reuptake inhibitors (SSRIs) led to the addition of black box warnings to antidepressant package inserts in 2004. Subsequently, a series of events appeared to result from these regulatory actions. Areas covered: This review provides an overview of the temporal associations of regulatory agencies' actions in North America and Europe with rates of depression diagnoses, pediatric antidepressant prescription rates, follow-up visits to physicians prescribing antidepressants, and rates of completed suicide and suicidal ideation in children and adolescents. In addition, evidence-based predictors of suicidal behavior and suicide risk, as provided by large, multisite studies of depressed children and adolescents, are outlined. Finally, this review considers key advancements in the study of young patients at risk for suicide and describes innovations in current research methodology, to more accurately identify suicidality and the relationship to antidepressant use within this vulnerable patient population. Expert opinion: Evaluating the role of antidepressants in those youths who do not respond to evidence-based psychotherapeutic interventions may be a useful future research direction. Until more data are available, however, closely monitored antidepressant treatment in combination with CBT may provide the most benefit.
KW - Antidepressants
KW - Children and adolescents
KW - Depressive disorders
KW - Suicidality
UR - http://www.scopus.com/inward/record.url?scp=84866495056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866495056&partnerID=8YFLogxK
U2 - 10.1517/14656566.2012.726613
DO - 10.1517/14656566.2012.726613
M3 - Review article
C2 - 22984934
AN - SCOPUS:84866495056
SN - 1465-6566
VL - 13
SP - 2119
EP - 2130
JO - Expert opinion on pharmacotherapy
JF - Expert opinion on pharmacotherapy
IS - 15
ER -